Study on Glofitamab-Based Treatment for People with Diffuse Large B-Cell Lymphoma

Inclusion Criteria

• Aged 65-79 years and considered unfit or frail, or aged 80 years and older at any fitness level.
• Diagnosed with DLBCL, HGBCL, or transformed lymphoma.
• No previous systemic treatment for lymphoma, except for short-term prednisone use.
• Advanced stage of disease (Stage 2 bulky, 3, or 4).
• Eligible for anthracycline treatment with adequate heart function.
• At least one measurable tumor by scan.
• Good overall health with a performance status score of 0 to 2.
• Adequate blood cell counts and organ function.
• Negative HIV test, or controlled HIV with stable treatment.
• Willing to sign informed consent and follow study procedures.
• Male participants must agree to use contraception and not donate sperm during and after treatment.

Exclusion Criteria

• Previous systemic treatment for lymphoma.
• Previous organ or stem cell transplants.
• Active cancer in the brain or spinal cord.
• Uncontrolled HIV, hepatitis B, or hepatitis C infections.
• Active infections or recent major surgery.
• Significant heart disease or uncontrolled autoimmune disorders.
• History of certain severe illnesses or conditions that could affect safety.
• Allergies to study drugs or similar medications.
• Recent use of certain cancer treatments or investigational therapies.
• Recent radiotherapy to specific areas.
• High-dose steroid use for non-lymphoma reasons.
• History of other cancers that could interfere with the study.
• Recent live vaccinations or plans to receive them during the study.